奥法木单抗联合减剂量CHOP方案治疗80岁及以上弥漫性大B细胞淋巴瘤:LYSA协作组开放标签、多中心、单臂、2期试验
该开放标签、多中心、单臂2期试验纳入120例80岁以上未经治疗的CD20阳性弥漫性大B细胞淋巴瘤患者,采用预治疗期后奥法木单抗联合减剂量CHOP方案。2年总生存率为64.7%(95%CI 55.3-72.7),中位总生存未达到(95%CI 30.2-未达到)。作者认为该方案似乎较既往报告数据改善总生存,可考虑作为随机临床试验的新治疗平台。
要点
- 80岁以上DLBCL患者接受奥法木单抗联合减剂量CHOP及预治疗,2年总生存率64.7%(95%CI 55.3-72.7)。
- 治疗期间45例死亡,其中28例(62%)死于淋巴瘤。
- 最常见不良反应为血液学毒性,3-4级中性粒细胞减少见于24例(21%)。
核心结论
- 作者认为,在80岁以上DLBCL患者中,奥法木单抗联合预治疗似乎较既往报告数据改善总生存。
- 作者认为,预治疗、抗CD20单克隆抗体与减剂量CHOP联合可考虑作为80岁以上DLBCL随机临床试验设计的新治疗平台。
研究设计与样本
- 开放标签、多中心、单臂2期试验,由LYSA协作组开展,在法国和比利时的41个学术和医院中心招募患者。
- 纳入80岁以上、未经治疗、组织学证实的CD20阳性DLBCL、Ann Arbor I至IV期患者120例。
- 主要终点为意向治疗人群的总生存,统计分析按意向治疗原则进行,试验注册号NCT01195714。
主要发现
- 2010年6月2日至2011年11月4日共入组120例患者,其中68例(57%)年龄调整国际预后指数为2-3。
- 中位随访时间26.8个月(IQR 24.5-30.1),2年总生存率64.7%(95%CI 55.3-72.7),中位总生存未达到(95%CI 30.2-未达到)。
- 治疗期间45例患者死亡,其中28例(62%)死于淋巴瘤。
- 治疗期间3-4级中性粒细胞减少24例(21%),血小板减少2例(2%),3-4级贫血6例(5%),发热性中性粒细胞减少7例(6%)。
- 改良意向治疗人群115例中,17例(15%)接受红细胞输注,3例(3%)接受血小板输注。
关键数值与推荐
- 预治疗期:口服长春新碱总剂量1 mg,第1周期前1周(第-7天)给药;口服泼尼松总剂量60 mg,第1周期前1周开始连用4天(第-7天至第-4天)。
- 奥法木单抗联合减剂量CHOP方案:每周期第1天静脉给予奥法木单抗总剂量1000 mg、多柔比星25 mg/m2、环磷酰胺400 mg/m2、长春新碱1 mg;第1-5天口服泼尼松40 mg/m2。
- 奥法木单抗给药时联合对乙酰氨基酚1000 mg和苯海拉明50 mg。
临床怎么用
- 作者认为,预治疗、抗CD20单克隆抗体与减剂量CHOP联合可考虑作为80岁以上DLBCL随机临床试验设计的新治疗平台。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2011 we reported a rituximab plus miniCHOP (reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone) combination for patients older than 80 years with diffuse large B-cell lymphoma (DLBCL). The 2-year overall survival was 59% (95% CI 49-67) with an excess of early toxicity. To improve those results we tested the same chemotherapy protocol in combination with ofatumumab and a pre-phase treatment. METHODS: For this open-label, multicentre, single-group, phase 2 trial, we recruited patients older than 80 years with untreated histologically-proven CD20-positive DLBCL, Ann Arbor stage I to IV, from 41 academic and hospital centres in France and Belgium. Patients received a pre-phase with oral vincristine (1 mg total dose 1 week before cycle 1 [day -7]) and oral prednisone (60 mg total dose starting 1 week before cycle 1, for 4 days [day -7 to day -4]) before the first cycle of the ofatumumab plus miniCHOP regimen. The regimen consisted of 1000 mg total dose of intravenous ofatumumab, 25 mg/m2 of intravenous doxorubicin, 400 mg/m2 of intravenous cyclophosphamide, and 1 mg of intravenous vincristine, on day 1 of each cycle; and 40 mg/m2 of oral prednisone on days 1-5. Ofatumumab was administered with 1000 mg of paracetamol and 50 mg of diphenhydramine. The primary endpoint was overall survival in the intention-to-treat population. The statistical analysis has been done on an intention-to-treat principle. This study was registered with ClinicalTrials.gov, number NCT01195714. FINDINGS: Between June 2, 2010, and Nov 4, 2011, we enrolled 120 patients. Age-adjusted International Prognostic Index was 2-3 in 68 (57%) of them. The median follow-up time was 26·8 months (IQR 24·5-30·1). The 2-year overall survival was 64·7% (95% CI 55·3-72·7) and median overall survival was not reached (95% CI 30·2-not reached). 45 patients died during the treatment, of whom 28 (62%) died due to lymphoma. The most common side-effect was haematological toxicity. Among the 120 patients, grade 3-4 neutropenia was reported in 24 (21%) patients and thrombocytopenia in two (2%), during the treatment period. Grade 3-4 anaemia was reported in six (5%) patients; seven (6%) patients had one episode of febrile neutropenia. 17 (15%) of 115 patients in the modified intention-to-treat population had red blood cell transfusions and three (3%) had platelet transfusions. INTERPRETATION: Our result suggest that, in patients older than 80 years with DLBCL, ofatumumab and pre-phase treatment seem to improve overall survival compared with the previously reported data. The combination of pre-phase treatment, a monoclonal antibody against CD20, and miniCHOP can be considered a new treatment platform for use in randomised clinical trial design for DLBCL treatment in patients older than 80 years. FUNDING: The Lymphoma Study Association, GlaxoSmithKline.
引用
- Peyrade F, Bologna S, Delwail V, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017. PMID: 28041583. doi:10.1016/S2352-3026(16)30171-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。